NCT05041595Enrolling By Invitation不适用
Collection of Whole Blood to be Used to Provide the Safety and Effectivenss of a Lyme Disease Diagnostic Assay to Support the Proposed Intended Use Statement and Product Labeling Claims.
适应症
试验速览
- 阶段
- 不适用
- 状态
- Enrolling By Invitation
- 入组人数
- 450
- 试验地点
- 1
- 主要终点
- Clinical Performance - Sensitivity
研究概览
简要总结
The primary objective is to obtain whole blood from subjects with signs and/or symptoms of early Borrelisois. Whole blood will also be obtained from subjects with suspicion of acute Borreliosis and under medical examination for Lyme disease.
In addition, whole blood will be obtained from apparently healthy subjects residing in areas endemic to Lyme disease and may also inlclude apparently healthy subjects residing in areas non-endemic to Lyme disease.
详细描述
Whole blood will be collected, and processed. Some blood will be transferred to additional tubes for further processing and aliquotting. Serum and plasma will be harvested and tested, at a later date, in a clinical performance study with approved and/or commercially available devices as well as an investigational Lyme assay. This study will be coordinated by the Sponsor.
研究设计
- 研究类型
- Observational
- 观察模型
- Cohort
- 时间视角
- Prospective
入排标准
- 性别
- All
- 接受健康志愿者
- 是
入选标准
- •Signs and symptoms of acute Lyme disease which include at least one of the following:
- •Recent onset of fatigue
- •Skin rash
- •Muscle aches
- •Neck pain
- •Joint pain or lymphadenopathy
- •Subgroup Borreliosis Subjects- restricted signs and symptoms of acute Lyme including EM Rash
- •Under physician or medical evaluation for acute on-set of Lyme Disease presenting with EM Rash
- •Detailed description of the EM rash (e.g. Itchy, painful, hot, vesicular, raised) with consent for photographic documentation is required including additional picture with ruler placing to confirming size.
- •EM rash with the following attributes:
- •Size > 5 cm in diameter
- •Appeared 3-30 days after bite or suspected bite
- •Specify Location (e.g. underarm or back of knee)
- •Subjects with confirmed early localized or disseminated Lyme Borreliosis manifestation
- •Signs and symptoms (e.g. Fever, Chills/Sweats, Headache, Fatigue/Tiredness, Myalgia/Sore muscles)
- •The EM rash has been present <42 days
- •Clinical diagnosis of Lyme disease is suspected by the practitioner
- •Ability to provide the minimum sample volume required
排除标准
- •Subjects unable to provide informed consent.
- •Subjects without clinical information and/or not meeting inclusion criteria.
- •Subjects having started antibiotic treatment > 5 days before inclusion.
- •Healthy Subjects
- •Inclusion Criteria:
- •Apparently healthy subjects with no present fever, chills, headache, fatigue, muscle and joint aches, and swollen lymph nodes, e.g. flu-like symptoms.
- •Ability to provide the minimum sample volume required.
- •Exclusion Criteria:
- •● Subjects unable to provide informed consent
- •Subjects without clinical information and/or not meeting inclusion criteria
- •Subjects with a recent diagnosis of Lyme disease, Anaplasmosis, Babesiosis, or history of known embedded tick bite which may have required 'manual extraction' NOTE: a tick just found on the subject or presence of a crawling tick is not considered a 'tick bite')
- •Subjects currently on antibiotic treatment.
- •Uncontrolled HIV-infection, if known. This is defined as an HIV-1 viral load >40 copies/mL and/or CD4+ count <500 x 106 cells/liter in the past 12 months.
- •Active syphilis or leptospirosis, if known
- •Active infection with Epstein Barr Virus (mononucleosis), if known
- •Active infection with Cytomegalovirus (CMV), if known
- •Subjects with autoimmune diseases, either confirmed rheumatoid arthritis and/or other autoimmune disorders diagnosed according to the leading guidelines
- •Current immunomodulation mediation including >7.5 mg prednisone daily, methotrexate, and/or biologicals. Medications such as hydroxychloroquine, sulfasalazine or NSAIDs are acceptable.
- •Immunodeficiency, hematologic malignancies in the medical history
- •Chemotherapy during the past year
结局指标
主要结局
Clinical Performance - Sensitivity
时间窗: Through study completion, an average of 1 year
Diagnostic Sensitivity
次要结局
- Clinical Performance - Specificity(Through study completion, an average of 1 year)
研究者
研究点 (1)
Loading locations...
相似试验
招募中
不适用
Prospective Collection of Whole Blood From Active Non-Small Cell Lung Cancer Patients for Supplemental ResearchNon Small Cell Lung CancerNCT05669105Sanguine Biosciences200
终止
不适用
Whole Blood Biospecimen Collection for Subjects With Chronic Granulomatous Disease (CGD)Chronic Granulomatous DiseaseNCT05915897Sanguine Biosciences6
终止
不适用
Whole Blood Biospecimen Collection for Subjects With Fanconi AnemiaFanconi AnemiaNCT05910853Sanguine Biosciences4
已完成
不适用
Access BNP Clinical Enrollment StudyHeart FailureNCT06624293Beckman Coulter, Inc.1,100
尚未招募
不适用
Collection of Peripheral Blood Mononuclear Cells From Healthy SubjectsDisease of the BloodNCT05560217Sun Yat-Sen Memorial Hospital of Sun Yat-Sen University50